{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T20:48:54Z","timestamp":1793134134143,"version":"4.5.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T00:00:00Z","timestamp":1582761600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T00:00:00Z","timestamp":1582761600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s00277-020-03949-z","type":"journal-article","created":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T11:03:31Z","timestamp":1582801411000},"page":"829-834","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["T315I mutation exerts a dismal prognosis on adult BCR-ABL1-positive acute lymphoblastic leukemia, and salvage therapy with ponatinib or CAR-T cell and bridging to allogeneic hematopoietic stem cell transplantation can improve clinical outcomes"],"prefix":"10.1007","volume":"99","author":[{"given":"Shi","family":"Ting","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xie","family":"Mixue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhu","family":"Lixia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Xueying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xie","family":"Wanzhuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4553-2751","authenticated-orcid":false,"given":"Ye","family":"Xiujin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,27]]},"reference":[{"issue":"2","key":"3949_CR1","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1182\/blood-2006-11-052373","volume":"110","author":"H Pfeifer","year":"2007","unstructured":"Pfeifer H, Wassmann B, Pavlova A, Wunderle L, Oldenburg J, Binckebanck A, Lange T, Hochhaus A, Wystub S, Br\u00fcck P, Hoelzer D, Ottmann OG (2007) Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood. 110(2):727\u2013734","journal-title":"Blood."},{"issue":"7","key":"3949_CR2","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1002\/cncr.28522","volume":"120","author":"S Soverini","year":"2014","unstructured":"Soverini S, De Benedittis C, Papayannidis C et al (2014) Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era. Cancer. 120(7):1002\u20131009","journal-title":"Cancer."},{"key":"3949_CR3","doi-asserted-by":"crossref","unstructured":"Pallera A, Altman JK, Berman E et al. NCCN guidelines insights: chronic myeloid leukemia, Version 1.2017. J Natl Compr Cancer Netw 2016; 14 (12): 1505\u20131512","DOI":"10.6004\/jnccn.2016.0162"},{"issue":"9","key":"3949_CR4","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.6004\/jnccn.2017.0147","volume":"15","author":"PA Brown","year":"2017","unstructured":"Brown PA, Shah B, Fathi A, Wieduwilt M, Advani A, Aoun P, Barta SK, Boyer MW, Bryan T, Burke PW, Cassaday R, Coccia PF, Coutre SE, Damon LE, DeAngelo D, Frankfurt O, Greer JP, Kantarjian HM, Klisovic RB, Kupfer G, Litzow M, Liu A, Mattison R, Park J, Rubnitz J, Saad A, Uy GL, Wang ES, Gregory KM, Ogba N (2017) NCCN guidelines insights: acute lymphoblastic leukemia, version 1.2017. J Natl Compr Cancer Netw 15(9):1091\u20131102","journal-title":"J Natl Compr Cancer Netw"},{"issue":"15","key":"3949_CR5","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1002\/cncr.30558","volume":"123","author":"FE Nicolini","year":"2017","unstructured":"Nicolini FE, Basak GW, Kim D, Olavarria E, Pinilla-Ibarz J, Apperley JF, Hughes T, Niederwieser D, Mauro MJ, Chuah C, Hochhaus A, Martinelli G, DerSarkissian M, Duh MS, McGarry L, Kantarjian HM, Cortes JE (2017) Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation. Cancer. 123(15):2875\u20132880","journal-title":"Cancer."},{"key":"3949_CR6","unstructured":"Yang F, Yang X, Bao X et al (2019) Anti-CD19 chimeric antigen receptor T-cells induce durable remission in relapsed Philadelphia chromosome-positive ALL with T315I mutation. Leuk Lymphoma:1\u20138"},{"key":"3949_CR7","doi-asserted-by":"publisher","first-page":"e238","DOI":"10.1038\/bcj.2014.60","volume":"4","author":"JF Seymour","year":"2014","unstructured":"Seymour JF, Kim DW, Rubin E et al (2014) A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood Cancer J 4:e238","journal-title":"Blood Cancer J"},{"issue":"8","key":"3949_CR8","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1080\/10428194.2016.1266623","volume":"58","author":"M Sumi","year":"2017","unstructured":"Sumi M, Sato K, Kaiume H et al (2017) Second cord blood transplantation and interferon-\u03b1 maintenance therapy for relapsed Ph+ acute lymphoblastic leukemia with the T315I mutation. Leuk Lymphoma 58(8):2005\u20132007","journal-title":"Leuk Lymphoma"},{"issue":"26","key":"3949_CR9","doi-asserted-by":"publisher","first-page":"5271","DOI":"10.1182\/blood-2009-04-219410","volume":"114","author":"FE Nicolini","year":"2009","unstructured":"Nicolini FE, Mauro MJ, Martinelli G et al (2009) Epidemiologic study on survival of chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia patients with BCR-ABL T315I mutation. Blood. 114(26):5271\u20135278","journal-title":"Blood."},{"issue":"1","key":"3949_CR10","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1016\/j.leukres.2011.08.011","volume":"36","author":"GF How","year":"2012","unstructured":"How GF, M\u00fcller MC, Lim LC (2012) Acquisition of the novel ABL kinase domain mutation T315L in a relapsed Philadelphia-positive acute lymphoblastic leukemia patient. Leuk Res 36(1):e20\u2013e21","journal-title":"Leuk Res"},{"issue":"7","key":"3949_CR11","first-page":"1","volume":"58","author":"D Wang","year":"2016","unstructured":"Wang D, Pan H, Wang Y (2016) T315L: a novel mutation within BCR-ABL kinase domain confers resistance against ponatinib. Leuk Lymphoma 58(7):1\u20133","journal-title":"Leuk Lymphoma"},{"key":"3949_CR12","first-page":"1","volume":"5","author":"H Zhang","year":"2019","unstructured":"Zhang H, He X, Ni D et al (2019) How does the novel T315L mutation of breakpoint cluster region-abelson (BCR-ABL) kinase confer resistance to ponatinib: a comparative molecular dynamics simulation study. J Biomol Struct Dyn 5:1\u201312","journal-title":"J Biomol Struct Dyn"},{"key":"3949_CR13","doi-asserted-by":"publisher","first-page":"4731","DOI":"10.2147\/OTT.S142482","volume":"10","author":"P Xu","year":"2017","unstructured":"Xu P, Guo D, Shao X et al (2017) Characteristics and mutation analysis of Ph-positive leukemia patients with T315I mutation receiving tyrosine kinase inhibitors. Oncotargets Ther 10:4731\u20134738","journal-title":"Oncotargets Ther"},{"issue":"6","key":"3949_CR14","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1038\/leu.2011.351","volume":"26","author":"A Spyridonidis","year":"2012","unstructured":"Spyridonidis A, Labopin M, Schmid C et al (2012) Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the Acute Leukemia Working Party of EBMT. Leukemia. 26(6):1211\u20131217","journal-title":"Leukemia."},{"key":"3949_CR15","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.exphem.2018.03.002","volume":"62","author":"G Ort\u00ed","year":"2018","unstructured":"Ort\u00ed G, Sanz J, Garc\u00eda-Cadenas I et al (2018) Analysis of relapse post transplant in acute leukemia, a comparative on second allogeneic hematopoietic cell transplant and donor lymphocyte infusions. Exp Hematol 62:24\u201332","journal-title":"Exp Hematol"},{"issue":"3","key":"3949_CR16","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s12185-008-0150-z","volume":"88","author":"M Yoshimitsu","year":"2008","unstructured":"Yoshimitsu M, Fujiwara H, Ozaki A, Hamada H, Matsushita K, Arima N, Tei C (2008) Case of a patient with Philadelphia-chromosome-positive acute lymphoblastic leukemia relapsed after myeloablative allogeneic hematopoietic stem cell transplantation treated successfully with imatinib and sequential donor lymphocyte infusions. Int J Hematol 88(3):331\u2013335","journal-title":"Int J Hematol"},{"issue":"1","key":"3949_CR17","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.leukres.2008.03.031","volume":"33","author":"M Tiribelli","year":"2009","unstructured":"Tiribelli M, Sperotto A, Candoni A, Simeone E, Buttignol S, Fanin R (2009) Nilotinib and donor lymphocyte infusion in the treatment of Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) relapsing after allogeneic stem cell transplantation and resistant to imatinib. Leuk Res 33(1):174\u2013177","journal-title":"Leuk Res"},{"issue":"4","key":"3949_CR18","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1159\/000492941","volume":"63","author":"MC Pirosa","year":"2018","unstructured":"Pirosa MC, Leotta S, Cupri A, Stella S, Martino EA, Scalise L, Sapienza G, Calafiore V, Mauro E, Spadaro A, Vigneri P, di Raimondo F, Milone G (2018) Long-term molecular remission achieved by antibody anti-CD22 and ponatinib in a patient affected by Ph\u2019+ acute lymphoblastic leukemia relapsed after second allogeneic hematopoietic stem cell transplantation: a case report. Chemotherapy. 63(4):220\u2013224","journal-title":"Chemotherapy."}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-03949-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-020-03949-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-03949-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T00:20:51Z","timestamp":1614298851000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-020-03949-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,27]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["3949"],"URL":"https:\/\/doi.org\/10.1007\/s00277-020-03949-z","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,27]]},"assertion":[{"value":"8 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Informed consent was obtained from the patient included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statement of informed consent"}}]}}